Physician profile
Kellie Neely
NPI 1437529369
$2,459.59
in general payments reported to CMS, 2019-2025
18 companies · $1,859 in 2025
The $1,859 reported for 2025 was more than what 94% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $137 · 2023: $260 · 2024: $204 · 2025: $1,859.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,322.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $406.42 | 2023-2025 | Jascayd, Ofev |
| Regeneron Healthcare Solutions, INC. | $373.84 | 2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $342.24 | 2023-2025 | Fasenra, Breztri, Tezspire |
| Glaxosmithkline, LLC. | $257.66 | 2025 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $216.63 | 2024-2025 | |
| Verona Pharma, INC. | $203.08 | 2025 | Ohtuvayre |
| Gilead Sciences, INC. | $136.92 | 2022 | |
| Lilly USA, LLC | $129.71 | 2025 | Zepbound |
| Grifols USA, LLC | $91.46 | 2025 | Xembify, Prolastin-C Liquid |
| Becton, Dickinson and Company | $85.58 | 2024-2025 | Hemosphere |
| Viatris Specialty LLC | $56.25 | 2025 | Yupelri |
| La Jolla Pharmaceutical Company | $34.75 | 2025 | Giapreza |
| 3b Medical, INC. | $25.70 | 2025 | Luna |
| Axsome Therapeutics, INC. | $23.14 | 2025 | Sunosi |
| Harmony Biosciences LLC | $22.60 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $20.53 | 2025 | Purified Cortrophin Gel |
| Takeda Pharmaceuticals U.S.A., INC. | $18.55 | 2025 | Glassia |
| Amgen INC. | $14.53 | 2025 | Tezspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kellie Neely listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.